ABBV · News · 20260903N

Product / Drug Pipeline Progress

AbbVie Inc. · 2026-09-03 · Importance 58 · Surprise 82

AbbVie’s investigational etentamig met both primary endpoints in the Phase 3 CERVINO trial for triple-class-exposed patients with relapsed/refractory multiple myeloma. The BCMA x CD3 bispecific T-cell engager produced a 74% objective response rate and reduced the risk of disease progression or death by 60% versus investigator-selected standard therapies, with a progression-free-survival hazard ratio of 0.40. Monthly dosing after a single step-up dose and low rates of cytokine release syndrome may support use in outpatient and community-oncology settings. The program remains behind rival bispecific antibodies from Johnson & Johnson, Pfizer, and Regeneron, but the results could improve AbbVie’s positioning in multiple myeloma and diversify its oncology pipeline.

Key facts

• Etentamig demonstrated low rates of cytokine release syndrome (CRS) and fatal infections with monthly dosing (Q4W) from initiation following a single step-up dose in the Phase 3 CERVINO trial. source